Logo
x

Search

Subscribe Now

BioMarin

BioMarin Receives the EMA’s CHMP Positive Opinion to Expand Use of Voxzogo (vosoritide) for Children Aged ≥4 Months with Achondroplasia

BioMarin Receives the EMA’s CHMP Positive Opinion to Expand Use of Voxzogo (vosoritide) for Children Aged ≥4 Months with Achondrop...

  • September 15, 2023
BioMarin’s Roctavian Receives the US FDA’s Approval for the Treatment of Severe Hemophilia A

BioMarin’s Roctavian Receives the US FDA’s Approval for the Treatment of Severe Hemophilia A

  • June 30, 2023
BioMarin's Reports the US FDA’s Acceptance of sNDA for Voxzogo (vosoritide) to Treat Children with Achondroplasia Aged ≤5 Years

BioMarin's Reports the US FDA’s Acceptance of sNDA for Voxzogo (vosoritide) to Treat Children with Achondroplasia Aged ≤5 Years

  • March 9, 2023
BioMarin’s Roctavian (valoctocogene roxaparvovec) Receives EC’s Conditional Marketing Authorization for Severe Hemophilia A

BioMarin’s Roctavian (valoctocogene roxaparvovec) Receives EC’s Conditional Marketing Authorization for Severe Hemophilia A

  • August 26, 2022
BioMarin to Presents Results of in P-I/II Study for the Treatment of Hemophilia A at ISTH 2022

BioMarin to Presents Results of in P-I/II Study for the Treatment of Hemophilia A at ISTH 2022

  • June 1, 2022
BioMarin’s Vimizin (elosulfase alfa) Receives NICE Recommendation for the Treatment of Mucopolysaccharidosis Type 4A

BioMarin’s Vimizin (elosulfase alfa) Receives NICE Recommendation for the Treatment of Mucopolysaccharidosis Type 4A

  • March 23, 2022
Image

Incisive News in 3 Shots.

Contact Us

Our Information

Follow Us

Copyright © 2024 PharmaShots - All Rights Reserved.